New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance

Drugs in Context

article

Kartikeya Tripathi¹  Joseph D Feuerstein² 

[1] Department of Medicine, St Vincent Hospital;Department of Medicine and Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School

关键词: colitis;    inflammatory bowel disease;    ulcerative colitis.;   

DOI  :  10.7573/dic.212572

学科分类：社会科学、人文和艺术（综合）

来源: C S F Medical Communications Ltd.

【 摘 要 】

Ulcerative colitis (UC) is a chronic idiopathic inflammatorydisorder that involves any part of the colon starting in therectum in a continuous fashion presenting typically withsymptoms such as bloody diarrhea, abdominal pain, and rectalurgency. UC is diagnosed based on clinical presentation andendoscopic evidence of inflammation in the colon startingin the rectum and extending proximally in the colon. Theclinical presentation of the disease usually dictates the choiceof pharmacologic therapy, where the goal is to first induceremission and then maintain a corticosteroid-free remission.There are multiple classes of drugs that are available and areused based on the clinical severity of the disease. For mild-tomoderate disease, oral or rectal formulations of 5-aminosalicylicacid are used. In moderate-to-severe UC, corticosteroidsare usually used in induction of remission with or withoutanother class of medications such as thiopurines or biologicsincluding anti-tumor necrosis factor, anti-integrins, or Januskinase inhibitors for maintenance of remission. Up to 15% ofthe patients may require surgery as they fail to respond tomedications and have risk of developing dysplasia secondary tolongstanding colitis.

【 授权许可】

CC BY-NC-ND